GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Background: GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (short half-life), initially necessitating short in...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2021-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|